|
 |
tamoxifen citrateThis page contains recent news articles, when available, and an overview of tamoxifen citrate but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: tamoxifen citrate (when available) Tamoxifen belongs to a class of drugs called selective estrogen receptor modulators (SERMs), which have both estrogenic and antiestrogenic effects. Tamoxifen has the same nucleus as diethylstilbestrol but possesses an additional side chain (trans isomer) which accounts for its antiestrogenic activity. Tamoxifen, chemically related to clomiphene., is used to in the therapy of metastatic breast cancer. for the treatment of breast cancer Mechanism Of Action: Tamoxifen binds to estrogen receptors (ER), inducing a conformational change in the receptor. This results in a blockage or change in the expression of estrogen dependent genes. The prolonged binding of tamoxifen to the nuclear chromatin of these results in reduced DNA polymerase activity, impaired thymidine utilization, blockade of estradiol uptake, and decreased estrogen response. It is likely that tamoxifen interacts with other coactivators or corepressors in the tissue and binds with different estrogen receptors, ER-alpha or ER-beta, producing both estrogenic and antiestrogenic effects. News Articles on Tamoxifen Featured Clinical Trial: Targeting Resistance to Endocrine Therapy ... - Apr 7, 2009 Phase III Randomized Study of Tamoxifen Citrate or Letrozole with Versus without Bevacizumab in Women with Hormone Receptor-Positive Stage IIIB-IV Breast National Cancer Institute - NCI Cancer Bulletin Does Reverse Payment Stifle the Innovation that the Patent Act ... - Apr 10, 2009 As the Second Circuit Court of Appeals states in Re: Tamoxifen Citrate Antitrust Litigation, "So long as the patent litigation is neither a sham nor BioWorld Online Life Sciences: Competition & Antitrust Update - Apr 1, 2009 5) epop; 6) flutamide capsules; 7) glipizide/metformin HCl tablets; 8) mirtazapine ODT; 9) tamoxifen citrate tablets; and 10) tetracycline HCl capsules. Linex Legal Federal Trade Commission Files Complaint Against Par ... - Feb 2, 2009 ...by numerous federal circuit and district courts, including by the Second Circuit in In re Tamoxifen Citrate Antitrust Litigation, 466 F.3d 187 (2d Cir. PR Newswire (press release), Federal Circuit Holds Reverse Payment Patent Settlements Lawful ... - Jan 22, 2009 ...(1) In so holding, the appeals court sided with several other courts, including the Second Circuit in In Re: Tamoxifen Citrate Antitrust Litigation, International Law Office, FTC Intervenes in Teva Pharmaceutical Industries’ Proposed $8.9 ... - Dec 20, 2008 3) desmopressin acetate tablets; 4) metoclopramide HCl tablets; 5) carboplatin injection; 6) tamoxifen citrate tablets; 7) metronidazole tablets; 7thSpace Interactive (press release), Researchers Uncover Cause Of Tamoxifen Resistance - Nov 13, 2008 Tamoxifen Citrate, sold under the brand name Nolvadex, is commonly used in conjunction with radiation to treat breast cancer. Nolvadex blocks some of the InjuryBoard.com, President Obama's Centrist Antitrust Enforcement - Nov 18, 2008 2005) and In re Tamoxifen Citrate Antitrust Litig. 429 F.3d 370 (2d Cir. 2005), the FTC lost its antitrust challenges to reverse payments. Law.com (registration), Cytogen Corporation - SWOT Analysis - New Research Report on ... - Nov 14, 2008 The company currently markets Quadramet (samarium Sm-153 lexidronam injection), Prostascint (capromab pendetide), and Soltamox (tamoxifen citrate) to the US Live-PR.com (Pressemitteilung), United States: Reverse Payment Patent Settlements: the Interplay ... - Oct 3, 2008 FTC 3 and In re Tamoxifen Citrate Antitrust Litigation 4 were appealed to the Supreme Court of the United States, which denied certiorari in both cases. Mondaq News Alerts (subscription), Ολυμπιακοί Αγώνες - Aug 19, 2008 Το σκεÏ?ασμα αποτελείται απο ακόμη δÏ?ο ουσίες, Îνα αντιοιστÏ?ογόνο (clomiphene citrate ή tamoxifen citrate) καθώς και βουπÏ?ενοÏ?φίνη, Îνα ισχυÏ?ÏŒ οπιοειδÎÏ‚ Sport24, 2008-07-02 21:13:17 - www.companiesandmarkets.com adds new report ... - Jul 2, 2008 The company currently markets Quadramet (samarium Sm-153 lexidronam injection), Prostascint (capromab pendetide), and Soltamox (tamoxifen citrate) to the US PR-Inside.com (Pressemitteilung), BUYINS.NET: WRE, NUJ, AKNS, BLTI, CYTO, JRJC Have Also Been ... - Apr 2, 2008 It markets QUADRAMET (samarium Sm-153 lexidronam injection), PROSTASCINT (capromab pendetide), and SOLTAMOX (tamoxifen citrate) to the United States Trading Markets (press release), OTCPicks.com Stocks to Watch for Wednesday, March 12th PMED - 12 Mar 2008 It markets QUADRAMET (samarium Sm-153 lexidronam injection), PROSTASCINT (capromab pendetide), and SOLTAMOX (tamoxifen citrate) to the United States TransWorldNews (press release), Clinical Oncology Publishes Findings from First-Ever Initiative on ... - Mar 11, 2008 AstraZeneca has provided the financial support for the five-year project and has donated (tamoxifen citrate) NOLVADEX and (anastrozole). ARIMIDEX. CSRwire.com (press release) This Month in Archives of General Psychiatry - Mar 3, 2008 Yildiz et al (SEE ARTICLE) tested the antimanic efficacy of the centrally active protein kinase C (PKC) inhibitor tamoxifen citrate in a randomized, Archives of General Psychiatry United States: FTC Takes 4-in-1 Shot At Reverse Payment ... - Feb 28, 2008 Barr Labs, Inc. (In re Tamoxifen Citrate Antitrust Litigation), 429 F.3d 370 (2d Cir. 2005), reprinted as amended, 466 F.3d 187 (2d Cir. Mondaq News Alerts (subscription), Shares of Cytogen rise on 3Q earnings - Nov 5, 2007 ...gain of $5.5 million and a non-cash impairment charge of $1.8 million associated with assets related to its tamoxifen citrate product, Soltamo. CNNMoney.com Cytogen Announces Quarterly Conference Call and Presentation at ... - Oct 25, 2007 ...(tamoxifen citrate) is the first liquid hormonal therapy approved in the US for the treatment of breast cancer in adjuvant and metastatic settings. WELT ONLINE, Cytogen Receives Nasdaq Notification Related to Minimum Bid Price - Nov 6, 2007 The Company also currently has US commercial rights to SOLTAMOX(TM) (tamoxifen citrate), a liquid hormonal therapy approved in the US for the treatment of PharmaLive.com (press release), Cytogen Reports Third Quarter 2007 Financial Results - Nov 5, 2007 ...as well as a non-cash impairment charge for approximately $1.8 million associated with assets related to its product, SOLTAMOXâ„¢ (tamoxifen citrate). Business Wire (press release), BUYINS.NET: GDP, ADG, GMO, CYTO, TRLG, SWTS Have Been Removed From ... - Oct 29, 2007 It markets QUADRAMET (samarium Sm-153 lexidronam injection), PROSTASCINT (capromab pendetide), and SOLTAMOX (tamoxifen citrate) to the United States Trading Markets (press release), Iran develops polymer to fight cancer - Oct 14, 2007 The new system made from polycaprolactone-folate can be used as a carrier for tamoxifen citrate, a commonly used chemotherapy drug in breast cancer patients PRESS TV, Cytogen to Present at the BIO Investor Forum 2007 - Oct 3, 2007 ...(tamoxifen citrate) is the first liquid hormonal therapy approved in the US for the treatment of breast cancer in adjuvant and metastatic settings. PharmaLive.com (press release), Cytogen Reports Second Quarter 2007 Financial Results - Aug 8, 2007 ...respectively, for the same periods in 2006, primarily due to costs associated with the launches of CAPHOSOL and SOLTAMOX(TM) (tamoxifen citrate). Genetic Engineering News (press release), ROTH 2007 New York Conference Presenter Profiles - Sep 4, 2007 PROSTASCINT(R) (capromab pendetide) is a PSMA-targeting monoclonal antibody-based imaging agent for prostate cancer and SOLTAMOX(TM) (tamoxifen citrate) is TMC Net, Cytogen to Present at Upcoming Investor Conferences in September - Aug 28, 2007 ...(tamoxifen citrate) is the first liquid hormonal therapy approved in the US for the treatment of breast cancer in adjuvant and metastatic settings. PharmaLive.com (press release), [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] Brand Names/Synonyms: tamoxifen citrate is also known by the following brand names and/or synonyms,Citrate; Apo-Tamox; CCRIS 3275; CTX; Citofen; Crisafeno; Diemon; Gen-Tamoxifen; HSDB 6782; Istubol; Kessar; Noltam; Nolvadex; Nolvadex-D; Nourytam; Novo-Tamoxifen; Oncomox; Pms-Tamoxifen; Retaxim; TRANS FORM OF TAMOXIFEN; Tamizam; Tamofen; Tamone; Tamoxasta; Tamoxen; Tamoxifen; Tamoxifen Citrate; Tamoxifen Drug Standard Solution; Tamoxifen and Its Salts; Tamoxifene [Inn-French]; Tamoxifeno [Inn-Spanish]; Tamoxifenum [Inn-Latin]; Trans-Tamoxifen; Valodex; Zemide Drug Category: tamoxifen citrate is categorized under the following by the FDA: Antineoplastic Agents; ATC:L02BA01 Dosage Forms: TABLET Absorption: Not Available Interactions: -->Interactions for Tamoxifen: When NOLVADEX is used in combination with coumarin-type anticoagulants, a significant increase in anticoagulant effect may occur. Where such coadministration exists, careful monitoring of the patientís prothrombin time is recommended. In the NSABP P-1 trial, women who required coumarin-type anticoagulants for any reason were ineligible for participation in the trial. There is an increased risk of thromboembolic events occurring when cytotoxic agents are used in combination with NOLVADEX. Tamoxifen reduced letrozole plasma concentrations by 37%. The effect of tamoxifen on metabolism and excretion of other antineoplastic drugs, such as cyclophosphamide and other drugs that require mixed function oxidases for activation, is not known. Tamoxifen and N-desmethyl tamoxifen plasma concentrations have been shown to be reduced when coadministered with rifampin or aminoglutethimide. Induction of CYP3A4-mediated metabolism is considered to be the mechanism by which these reductions occur; other CYP3A4 inducing agents have not been studied to confirm this effect. One patient receiving NOLVADEX with concomitant phenobarbital exhibited a steady state serum level of tamoxifen lower than that observed for other patients (ie, 26 ng/mL vs. mean value of 122 ng/mL). However, the clinical significance of this finding is not known. Rifampin induced the metabolism of tamoxifen and significantly reduced the plasma concentrations of tamoxifen in 10 patients. Aminoglutethimide reduces tamoxifen and N desmethyl tamoxifen plasma concentrations. Medroxyprogesterone reduces plasma concentrations of N-desmethyl, but not tamoxifen. Concomitant bromocriptine therapy has been shown to elevate serum tamoxifen and N-desmethyl tamoxifen. Drug/Laboratory Testing Interactions: During postmarketing surveillance, T4 elevations were reported for a few postmenopausal patients which may be explained by increases in thyroid-binding globulin. These elevations were not accompanied by clinical hyperthyroidism. Variations in the karyopyknotic index on vaginal smears and various degrees of estrogen effect on Pap smears have been infrequently seen in postmenopausal patients given NOLVADEX. In the postmarketing experience with NOLVADEX, infrequent cases of hyperlipidemias have been reported. Periodic monitoring of plasma triglycerides and cholesterol may be indicated in patients with pre-existing hyperlipidemias . |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |